Developing novel peptide-based therapeutics and technologies to mitigate fibrosis

开发新型肽疗法和技术来减轻纤维化

• 批准号: nhmrc : 2001278
• 金额: $ 116.14万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-novel-peptide-mitigate-fibrosis/1779747
• 关键词: Developing; novel; peptide; based; therapeutics

Fibrosis (tissue scarring) is an unmet medical problem that adversely affects both human health and medical devices. It causes organ (e.g. heart, kidney) failure leading to death. Fibrotic encapsulation causes medical device (e.g. surgical mesh) failure. Our team has discovered a peptide, B7-33, that mitigates fibrosis in the short-term. Our IDEAS grant aims to develop long-acting B7-33 therapies and, to employ long-acting B7-33 mimetics in anti-fibrotic compositions for surgical meshes.

纤维化(组织瘢痕形成)是一个尚未解决的医学问题，对人类健康和医疗器械都有不利影响。它会导致器官(如心脏、肾脏)衰竭，导致死亡。纤维性包囊导致医疗器械(如外科网状物)失效。我们的团队发现了一种多肽B7-33，可以在短期内缓解纤维化。我们的想法基金旨在开发长效B7-33疗法，并将长效B7-33模拟物用于外科网眼的抗纤维化组合物。